Skip to content
Camelot BioCapital
  • About Us
    • Management Team
    • Scientific & IP Advisory Board
  • Pipeline
  • Past Partner Deals
  • Past and Current
    Partners & Affiliates
  • News
  • Contact Us
Menu
Home » News

News

iOncologi, Inc. Acquires TargImmune Therapeutics to Expand and Strengthen Immunotherapy Pipeline Against Solid Tumors

March 17, 2025
Read More

Peter Kash: 2026 Healthcare Trends

March 10, 2025
Read More

Cancer Vaccine Tested in Glioblastoma Patients Shows Potential of mRNA Aggregates

May 1, 2024
Read More
  • NYC
  • Palm Beach
  • Tel Aviv
  • Perth
  • Basel
  • Gainesville
  • Home
  • About Us
  • Pipeline
  • Past Partner Deals
  • Past and Current Partners & Affiliates
  • News
  • Contact Us
  • Sitemap

Investments in private placements involve a high degree of risk and may result in a partial or total loss of your investment. Private placements are generally illiquid investments. Investors should consult with their investment, legal, and tax advisors regarding any private placement investment.

All members of Camelot Investment Services, LLC are registered representatives and Securities offered through Stonehaven, LLC – Member FINRA/SIPC . Regulatory disclosures: Disclaimers & Risks, Privacy Policy and Form CRS.

© Camelot BioCapital. All rights reserved
Website by Axxiem
Scroll to top